Skip to content
Vijaya Diagnostic Centre logo

Vijaya Diagnostic Centre

VIJAYA NSE
₹1,572.30 +61.70 (+4.08%)
Market Cap
₹16,194 Cr
P/E
79.45
View as Markdown
MCP
Close 20 Nov 2026 ₹1,572.30 1Y +543.30 +52.8%
Start ₹1,029.00

Key Fundamentals

SmallcapHealthcare ServicesHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
20.50%
Debt to Equity
0.48
EPS (TTM)
₹19.79
Book Value
₹102.62
Market Cap
₹16,194 Cr
P/E (TTM)
79.45
P/B
15.32
ROE
18.90%
Dividend Yield
0.13%
EBITDA
₹358 Cr
52W High
₹1,593.60
52W Low
₹848.00
Day Range
₹1,500.30 – ₹1,587.00
Volume
5,38,498

Peer Comparison

Healthcare › Healthcare Services › Healthcare Service Provider

Vijaya Diagnostic Centre peer comparison
2,006.0057.4833,67012.270.51%22.30%28.00%3,034587
1,572.3079.4516,19415.320.13%18.90%20.50%911203
566.0052.3111,7387.150.18%13.60%17.80%1,778225
528.4558.338,41115.212.78%28.40%35.40%930143
655.8051.396,5955.550.00%8.83%15.30%1,110128
519.0516.671,6841.600.39%10.90%12.70%783100
311.5038.791,6225.880.14%14.20%17.30%34641
Median 7 companies566.0052.318,4117.150.18%14.20%17.80%930143

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

47 Average

Data confidence 100/100

Category scores

Quality
72
Strong
Returns, margins, earnings quality 22% weight
Valuation
17
Poor
Cheap vs sector & own history 24% weight
Growth
68
Strong
Sales & profit trajectory 9% weight
Financial Health
42
Weak
Solvency, leverage, coverage 9% weight
Momentum
58
Good
Trend strength, vol-adjusted 12% weight
Ownership
43
Weak
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

No strengths listed

Weaknesses

1
  • Stock is trading at 15.3 times its book value

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish3412
OscillatorsBearish342
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
65.19
Neutral
MACD (12,26,9)
21.05
Bullish
SMA (50)
1,458.30
Bullish
SMA (200)
1,269.20
Bullish

As of

Analyst Rating

Based on 8 analysts
BUY88%

7 of 8 analysts rate Buy, 1 Hold, 0 Sell.

As of

BUY
7
88%
HOLD
1
13%
SELL
0
0%

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
5Y+16.64%
3Y+21.04%
1Y+19.53%
TTM+24.32%

Net profit

Net profit growth by window
5Y+15.27%
3Y+26.73%
1Y+20.14%
TTM+33.55%

Operating cash flow

Operating cash flow growth by window
5Y+15.83%
3Y+17.99%
1Y+20.98%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y−2.63 pp
3Y+1.75 pp
1Y+1.31 pp
TTM+3.41 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2018₹251 Cr
Mar 2019₹293 Cr
Mar 2020₹339 Cr
Mar 2021₹377 Cr
Mar 2022₹462 Cr
Mar 2023₹459 Cr
Mar 2024₹548 Cr
Mar 2025₹681 Cr
Mar 2026₹814 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2018₹35.00 Cr
Mar 2019₹46.00 Cr
Mar 2020₹63.00 Cr
Mar 2021₹85.00 Cr
Mar 2022₹111 Cr
Mar 2023₹85.00 Cr
Mar 2024₹120 Cr
Mar 2025₹144 Cr
Mar 2026₹173 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹444 Cr +24.2% vs FY26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 19 Nov 2026
AI opinion · based on fundamentals
Risk high

Vijaya Diagnostic Centre Ltd trades at ₹1,510.6 as of 2026-11-19 with a market cap of ₹15,558.83 crore, a PE of 76.33x and ROE of 18.07%. The stock has delivered a 1-year CAGR of 49% and compounded profit growth of 33% TTM, but trades at 14.71x book value, reflecting a rich valuation relative to its earnings base.

Bull Case 8
  • Strong revenue momentum with TTM compounded sales growth of 24% and a 3-year compounded sales CAGR of 21%, indicating consistent top-line expansion in the diagnostics space
  • TTM compounded profit growth of 33% outpaces sales growth of 24%, suggesting improving operating leverage and margin expansion
  • Stock has delivered a 1-year CAGR of 49%, significantly outperforming broader market indices and reflecting strong investor confidence
  • Consistent ROE of 19% over the last 1, 3 and 5-year periods demonstrates stable and efficient capital deployment
  • ROCE of 19.22% as of 2026-11-19 indicates the business generates healthy returns on total capital employed, including debt
  • Conservative balance sheet with a debt-to-equity ratio of just 0.44, providing financial flexibility for future expansion without excessive leverage
  • 3-year stock CAGR of 34% and 5-year stock CAGR of 21% show sustained long-term wealth creation for shareholders
  • 5-year compounded profit growth of 15% and 5-year compounded sales growth of 17% demonstrate the company has maintained a durable growth trajectory over a multi-year period
Bear Case 6
  • PE ratio of 76.33x as of 2026-11-19 is extremely elevated, requiring sustained high earnings growth over many years to justify the current price
  • Dividend yield of just 0.13% offers negligible income return to shareholders, meaning returns depend almost entirely on capital appreciation
  • At ₹1,510.6 the stock trades near its 52-week high of ₹1,593.6, just 5.2% below the peak, raising the risk of mean reversion after a sharp rally from the 52-week low of ₹848
  • The gap between 5-year compounded profit growth of 15% and the current PE of 76.33x implies a PEG ratio well above 1, suggesting the valuation may be running ahead of the longer-term earnings growth trajectory
  • Market cap of ₹15,558.83 crore against TTM EPS of ₹19.79 means any deceleration in the 33% TTM profit growth rate could trigger a sharp de-rating of the multiple
  • ROE of 18.07% is respectable but not exceptionally high for a capital-light diagnostics business trading at 14.71x price-to-book, raising questions about whether such a premium is warranted

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

1d ago

TL;DR: Vijaya Diagnostic is delivering strong growth with Q2FY27 profit up 35% and revenue up 27.4% YoY, reflecting solid operational expansion in the diagnostics space. No material headwinds surfaced in the recent news cycle. The upcoming investor meet signals continued engagement with institutional investors. The growth trajectory looks healthy, and sustained revenue expansion will be key to watch in coming quarters.

Positives 1
  • Q2FY27 PAT surges 35% YoY Nov 03

    Standalone net profit rose 35% YoY to ₹579.2 lakh in Q2FY27. Revenue grew 27.4% YoY to ₹242 crore, driven by operational expansion.

Neutral 2
  • Investor meet in Chennai Nov 18

    Vijaya Diagnostic will hold an analyst and institutional investor meeting in Chennai on December 11, 2026.

  • New Company Secretary appointed Nov 03

    Rahul Jain appointed as Company Secretary and Compliance Officer effective November 3, 2026, following Board approval under SEBI regulations.

Quarterly Results

₹ Cr
VIJAYA quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
139
133
155
156
183
169
173
188
202
205
219
231
255
Expenses
82
80
92
95
107
102
104
115
120
119
124
132
143
Operating Profit
57
52
63
61
76
67
69
74
82
86
96
99
113
OPM %
41%
39%
41%
39%
42%
40%
40%
39%
41%
42%
44%
43%
44%
Other Income
7
5.11
3
4
5
5
5
7
6
5
2
9
4.95
Interest
6
6
6
6
6
7
7
7
8
9
9
11
11.38
Depreciation
14
15
16
17
17
18
19
21
22
24
24
25
26.9
PBT
45
35
44
42
57
47
47
52
58
58
64
71
79.42
Tax %
25%
25%
23%
25%
26%
24%
26%
26%
25%
26%
25%
25%
25%
Net Profit
34
26
34
32
42
35
35
39
43
43
48
53
59.47
EPS (₹)
3.26
2.53
3.27
3.06
4.10
3.43
3.40
3.76
4.21
4.20
4.66
5.16
5.77
YoY Sales growth
15
17
28
29
32
27
12
20
10
21
27
23
27

Profit & Loss

₹ Cr
VIJAYA profit and loss, annual, ₹ crore
Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
251
293
339
377
462
459
548
681
814
911
Expenses
171
184
206
211
259
277
327
408
477
518
Operating Profit
80
108
133
166
204
182
221
273
337
393
OPM %
32%
37%
39%
44%
44%
40%
40%
40%
41%
43%
Other Income
7
10
15
12
13
14
20.82
17
21
21
Interest
5
14
15
15
16
21
24
27
33
40
Depreciation
26
40
49
50
53
62
57
71
92
101
PBT
55
65
83
112
147
114
159
193
233
273
Tax %
37%
29%
25%
24%
25%
25%
25%
26%
26%
—
Net Profit
35
46
63
85
111
85
120
144
173
204
EPS (₹)
3.44
4.50
6.13
8.29
10.76
8.29
11.61
14.01
16.81
19.79
Div. Payout %
0%
0%
0%
0%
9%
12%
9%
14%
12%
—
Sales growth
—
17
16
11
23
−1
19
24
19
24

Balance Sheet

₹ Cr
VIJAYA balance sheet, annual, ₹ crore
Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
5
5
5
5
10
10
10
10
10
10
Reserves
157
203
270
354
458
535
647
789
947
1,047
Borrowings
33
146
161
141
183
248
259
320
423
509
Other Liabilities
39
53
46
41
62
61
66
155
127
167
Total Liabilities
234
406
482
541
713
853
983
1,274
1,507
1,733
Fixed Assets
119
259
272
268
370
524
742
865
1,069
1,185
CWIP
3
3
10
9
34
28
9
70
35
33
Investments
73
69
55
28
54
139
109
185
228
304
Other Assets
39
76
146
236
255
163
123
154
174
212
Total Assets
234
406
482
541
713
853
983
1,274
1,507
1,733

Cash Flow

₹ Cr
VIJAYA cash flow, annual, ₹ crore
Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
62
91
106
130
158
165
183
224
271
Investing
−98
−90
−31
−130
−123
−110
−141
−182
−174
Financing
−8
−7
−30
−49
−31
−42
−45
−52
−69
Net Cash Flow
−44
−6
46
−49
4
13
−2
−9
27
Free Cash Flow
32
31
69
98
37
40
99
132
91
CFO/EBITDA
103
101
98
97
97
105
98
97
96

Ratios

VIJAYA financial ratios, annual
Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
12
11
9
6
8
8
11
8
9
Inventory Days
24
20
23
17
22
13
29
21
19
Days Payable
176
196
180
142
110
172
184
143
145
Cash Conversion Cycle
−140
−165
−149
−118
−81
−152
−144
−114
−117
Working Capital Days
−41
−51
−49
−26
−34
−36
−29
−48
−37
ROCE %
—
28%
23%
27%
28%
18%
20%
21%
21%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Vijaya Diagnostic Centre insights

63 extracted metrics across FY18–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 52.46%
  • DIIs 32.50%
  • FIIs 10.66%
  • Public 3.55%
  • Others 0.83%

1.96% of promoter holding pledged as of Sep 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Vijaya Diagnostic Centre

What does Vijaya Diagnostic Centre Ltd do?
Vijaya Diagnostics Centre limited is a leading diagnostic medicare services provider in Southern India and offers comprehensive services that include nuclear medicine, radiology, laboratory, health check-ups and medical services.
Where is Vijaya Diagnostic Centre Ltd (VIJAYA) listed?
Vijaya Diagnostic Centre Ltd trades as VIJAYA on the NSE and under code 543350 on the BSE.
Which sector does Vijaya Diagnostic Centre Ltd belong to?
Vijaya Diagnostic Centre Ltd is classified under the Healthcare sector, in the Healthcare Services industry.
What is the market capitalisation of Vijaya Diagnostic Centre Ltd?
Vijaya Diagnostic Centre Ltd has a market capitalisation of ₹16,194 Cr as of 20 Nov 2026, which places it in the Smallcap band.
What is the PE ratio of Vijaya Diagnostic Centre Ltd?
Vijaya Diagnostic Centre Ltd trades at a PE ratio of 79.45 as of 20 Nov 2026, on earnings per share of ₹19.79, against a book value of ₹102.62 per share.
What is the 52-week high and low of Vijaya Diagnostic Centre Ltd?
Over the last 52 weeks Vijaya Diagnostic Centre Ltd has traded between ₹848 and ₹1,593.6 as of 20 Nov 2026.
Does Vijaya Diagnostic Centre Ltd pay dividends?
Vijaya Diagnostic Centre Ltd has a dividend yield of 0.13%.
What is the Return on Equity (ROE) of Vijaya Diagnostic Centre Ltd?
Vijaya Diagnostic Centre Ltd reported a return on equity of 18.90%. Its debt-to-equity ratio is 0.48.

Company Information

Vijaya Diagnostics Centre limited is a leading diagnostic medicare services provider in Southern India and offers comprehensive services that include nuclear medicine, radiology, laboratory, health check-ups and medical services. The company provides its services across 13 cities through its 81 diagnostic centers and 11 reference laboratories.

Listed 14 Sep 2021
Face Value ₹1
Shares Outstanding 10,29,97,715

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/VIJAYA.md for Vijaya Diagnostic Centre Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More